Search results
Sanofi's (SNY) Dupixent Gets FDA Nod for Eczema in Infants
Zacks via Yahoo Finance· 2 years agoSanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants...
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
Zacks via Yahoo Finance· 2 months agoASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with...
Regeneron Breaks Out On Home Run In 'Smoker's Lung' As Sanofi Soars
Investor's Business Daily· 1 year agoSanofi and Regeneron Pharmaceuticals' asthma drug Dupixent succeeded in a final-phase study of...
Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis
Benzinga via Yahoo Finance· 2 years agoThe FDA approved Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Dupixent...
US FDA approves Dupixent to treat younger kids with esophageal condition
Reuters via Yahoo News· 4 months ago(Reuters) -The U.S. health regulator has approved the use of Regeneron and Sanofi's Dupixent to...
Sanofi Raises Profit Guide And Reverses A Drug-Pricing Pitfall
Investor's Business Daily· 2 years agoSanofi stock ended flat Thursday — reversing earlier declines — despite lifting its profit guidance...
Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again
Investor's Business Daily· 4 months agoThere's more than Eylea to like about Regeneron Pharmaceuticals right now, an analyst said Friday as...
Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales
Benzinga via Yahoo Finance· 1 year agoFrench drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in...
Lilly (LLY) Eczema Candidate Keeps Skin Clearance for One Year
Zacks via Yahoo Finance· 2 years agoData from late-stage studies conducted by Eli Lilly (LLY) shows that its atopic dermatitis drug...
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
Motley Fool via Yahoo Finance· 2 weeks agoThe phrase "the golden age of biotech" was somewhat popular a few years ago but now seems largely...